Especially, an association study between CDKN2 deletion and clinical outcomes suggested CDKN2 as a poor prognostic marker, and this has been observed in 29 % of BCR-ABL-positive ALL [5]. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.